The chapter explores the potential impact of geroprotectors on human lifespan, comparing it to the hypothetical scenario of curing cancer. It discusses the increases in lifespan seen in rodent studies and the uncertainty of the exact effect size in humans. The speakers also address the limitations of current medications and the desire for a longer, healthier lifespan and its implications on society.
The Sunday Times’ tech correspondent Danny Fortson brings on Alex Colville, co-founder of Age1, to talk about funding longevity science (3:15), studying the biology of ageing (5:10), the snake oil problem (11:05), the rise of “geroscience” (15:15), healthspan (23:05), the ageing hypothesis (26:55), the potential of metformin (30:05), working on an anti-ageing treatment (34:15), and how long he thinks we’ll live (38:45).
Hosted on Acast. See acast.com/privacy for more information.